Phase 2
N=61
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Bottom Line
View on ClinicalTrials.gov: NCT00989664 ↗Enrolled (actual)
61
Serious AEs
50.0%
Results posted
Apr 2012
Primary outcome: Primary: Number of Participants (Par.) Receiving TST and I 131 TST With a Response >=30 Days Versus Par. With a Response >=30 Days After Their Last Qualifying Chemotherapy Regimen (LQCR), Masked Independent Randomized Radiology and Oncology Review (MIRROR) Panel — 26; 5 participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Tositumomab and Iodine I 131 Tositumomab (Biological)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Jan 2004
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants (Par.) Receiving TST and I 131 TST With a Response >=30 Days Versus Par. With a Response >=30 Days After Their Last Qualifying Chemotherapy Regimen (LQCR), Masked Independent Randomized Radiology and Oncology Review (MIRROR) Panel |
26; 5 | <0.001 sig |
| PRIMARY Duration of Response for Par. Receiving TST and I 131 TST With a Response >=30 Days Versus the Number of Par. With a Response >=30 Days After Their LQCR, as Assessed by the MIRROR Panel |
6.5; 3.5 | — |
| SECONDARY Number of Participants With Any Uncofirmed Response (CR, Clinical Complete Response [CCR], or PR), CR, CCR, CR+CCR, and PR), as Assessed by the Investigator |
39; 11; 1; 12; 27 | — |
| SECONDARY Number of Participants With Any Confirmed Response (CR, CCR, or PR), Confirmed CR, Confirmed CCR, Confirmed CR+CCR, and Confirmed PR, as Assessed by Investigator |
30; 9; 1; 11; 18 | — |
| SECONDARY Time to Progression of Disease or Death, as Assessed by the Investigator |
4.7 | — |
| SECONDARY Time to Treatment Failure, as Assessed by the Investigator |
4.6 | — |
| SECONDARY Overall Survival |
30.1 | — |
| SECONDARY Number of Participants With Responses of CR, CCR, CR+CCR, and PR Following TST and I 131 TST and Following the LQCR, as Assessed by the Investigator |
39; 17; 11; 1; 1; 1 | — |
| SECONDARY Number of Participants With the Indicated Adverse Events (AE) Related to Study Drug Experienced by at Least 5% of Participants |
35; 29; 29; 13; 27; 19 | — |
| SECONDARY Number of Participants With the Indicated Grade 3 or Grade 4 AEs Experienced by at Least 5% of Participants |
35; 29; 29; 13; 4; 9 | — |
| SECONDARY Number of Participants With the Indicated Grade 3 or Grade 4 AEs Related to Study Drug and Experienced by at Least 5% of Participants |
35; 29; 29; 13; 9; 8 | — |
| SECONDARY Number of Participants With the Indicated Primary Cause of Death |
37; 0; 11 | — |
| SECONDARY Number of Participants With the Indicated Time to Death From the Last Dose of Study Drug |
1; 47 | — |
| SECONDARY Number of Participants With the Indicated Fatal Serious Adverse Events (SAE) Unrelated to Study Drug |
1; 2; 1; 1 | — |
| SECONDARY Number of Participants With the Indicated Fatal SAEs Related to Study Drug |
1; 2; 1; 1 | — |
| SECONDARY Number of Participants With the Indicated SAEs Related to Study Drug |
4; 2; 1; 1; 1; 1 | — |
| SECONDARY Number of Participants With the Indicated Type of Infection |
15; 44; 0; 5; 14 | — |
| SECONDARY Number of Participants With an Infection for Which Anti-infectives Were Administered |
12; 3 | — |
| SECONDARY Number of Participants Who Were Negative for Human Anti-murine Antibodies (HAMA) at Baseline (Before Receiving the Dosimetric Dose) But Positive or Negative After Receiving the Dosimetric Dose |
5; 53 | — |
| SECONDARY Time to HAMA Positivity From the First Dosimetric Dose |
279 | — |
| SECONDARY Number of Participants With the Indicated Grade 3 or Grade 4 Hematologic Toxicities |
35; 13; 29; 29 | — |
| SECONDARY Number of Participants With Hypothyroidism Prior to Therapy and After the Therapeutic Dose |
8; 7 | — |
Summary
The results from Phase 1/2 (RIT-I-000) and Phase 2 (RIT-II-001) studies of Tositumomab and Iodine I 131 Tositumomab (TST/I-131 TST) demonstrated that TST/ I-131 TST produced a high response rate in patients with chemotherapy-relapsed/refractory, low-grade or transformed low-grade Non-Hodgkin's Lymphoma (NHL). On the basis of these results this study was designed to compare the efficacy of TST/ I-131 TST to the last qualifying chemotherapy regimen in patients with chemotherapy-refractory, low-grade or transformed low-grade NHL.
Eligibility Criteria
Inclusion Criteria
- Male and female subjects ≥18 years of age with histologically confirmed at initial diagnosis, previously treated (at least 2 prior chemotherapy regimens), low-grade NHL or low-grade lymphoma that had transformed to intermediate- or high-grade histology.
Exclusion Criteria
- Subjects with more than an average of 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry. Bilateral posterior iliac crest core biopsies are required if the percentage of intratrebecular space involved exceeds 10% in a unilateral biopsy. The mean of bilateral biopsies must be no more than 25%.
- Cytotoxic chemotherapy, radiation therapy, immunosuppressants, or cytokine treatment within 4 weeks prior to study entry or persistent clinical evidence of toxicity.
- Prior stem cell transplant.
- Active obstructive hydronephrosis.
- Evidence of active infection requiring intravenous (IV) antibiotics at the time of study entry.
- New York Heart Association Class III or IV heart disease or other serious illness that would preclude evaluation.
- Prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the subject has been disease-free for 5 years.
- Known HIV infection.
- Known brain or leptomeningeal metastases.
- Subjects who are pregnant or nursing.
- Previous allergic reactions to iodine. This does not include reactions to intravenous iodine-containing contrast materials.
- Prior exposure to monoclonal or polyclonal antibodies of any non-human species for either diagnostic or therapeutic purposes, including engineered chimeric and humanized antibodies.
- Prior radioimmunotherapy.
- Progressive disease within 1 year of irradiation arising in a field that has been previously irradiated with >3500 cGy.
- Current use of either approved or non-approved (through another protocol) anti-cancer drugs or biologics
- De novo intermediate- or high-grade lymphoma.
Data sourced from ClinicalTrials.gov (NCT00989664). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.